Company: PSTV
Filing Date: 2025-04-01
Form Type: PRER14A
Source: 0001140361-25-011649
Chunk: 37

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-01
Form: PRER14A
Chunk 37
---
 the Warrant Amendment Proposal (the “Adjournment Proposal”). If the Adjournment Proposal is approved, the Special Meeting could be successively adjourned to another date. In addition, the Board could postpone the Special Meeting before it commences, whether for the purpose of soliciting additional proxies or for other reasons. If the Special Meeting is adjourned for the purpose of soliciting additional proxies, stockholders who have already submitted their proxies will be able to revoke them at any time prior to their exercise at the adjourned meeting.

**Interest of Certain Persons in Matters to Be Acted Upon**

Our executive officers and directors who hold May 2024 Warrants have an interest in this Proposal No. 5 because if the Warrant Amendment Proposal is approved, they will have additional time to exercise those Warrants and therefore the value of their ownership of those warrants may increase.

#### Vote Required
If a quorum is represented at the Special Meeting, approval of this Proposal No. 5 requires the affirmative vote of a majority of the Common Stock having voting power present, virtually or by proxy. Abstentions are considered shares present and entitled to vote and thus will have the effect of a vote “AGAINST” this proposal. Broker non-votes will have no effect on the results of this vote.

If a quorum is not represented at the Special Meeting, approval of this Proposal No. 5 requires the affirmative vote of a majority of the shares of Common Stock present, virtually or by proxy. In this case, abstentions will have the effect of a vote “AGAINST” Proposal No. 5 and broker non-votes will have no effect.

#### Board Recommendation
**OUR BOARD UNANIMOUSLY RECOMMENDS THAT THE STOCKHOLDERS VOTE “FOR” THIS PROPOSAL NO. 5 TO ADJOURN THE SPECIAL MEETING, IF NECESSARY, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE NOT SUFFICIENT VOTES IN FAVOR OF THE OTHER PROPOSALS.**

<div align='center'>22</div>

TABLE OF CONTENTS

STOCK OWNERSHIP INFORMATION The following table sets forth information with respect to the beneficial ownership of our Common Stock as of March 4, 2025, for:

| • | each person, or group of affiliated persons, known by us to be the beneficial owner of more than 5% of our outstanding shares of Common Stock; |

| • | each of our named executive officers; |

| •